SABCS20: Circulating tumor cells can predict response in metastatic breast cancer
/ BestPractice Nordic toimitus
SABCS20: Trastuzumab deruxtecan is a promising new treatment for HER2 positive metastatic breast cancer
/ BestPractice Nordic toimitus
SABCS20: Abemacitib continues to show promising results in early breast cancer
/ BestPractice Nordic toimitus
SABCS20: Positive results of pembrolizumab in 1L for triple negative breast cancer regardless of chemotherapy partner
/ BestPractice Nordic toimitus
SABCS20: Postmenopausal women with early breast cancer and low risk score could skip adjuvant chemotherapy
/ BestPractice Nordic toimitus